Eli Lilly and Co.’s oral selective estrogen receptor degrader (SERD) imlunestrant has been approved by the U.S. FDA for ...

Youthbio Therapeutics Inc. has held a successful INTERACT meeting with the FDA for its lead Alzheimer’s candidate, YB-002.

Coronary artery bypass graft (CABG) surgery remains the gold standard treatment for patients with severe atherosclerosis, but ...

Boehringer Ingelheim Pharma GmbH & Co KG has advanced a novel T-cell engager resulting from a collaboration with Numab ...

The U.S. FDA released a trio of draft guidances to help sponsors in developing and monitoring cell and gene therapies, as ...

Rakuten Medical Inc. is advancing a pipeline of solid tumor therapeutics built on its Alluminox platform worldwide, having ...

Is there a link between cellular senescence and multiple sclerosis (MS) progression? Several presentations at this year’s ...

The threat of tariffs on imports of branded drugs is about to be realized after U.S. President Donald Trump announced a 100% ...

The Trump administration has launched an investigation into the national security effects of imports of medical equipment, ...

Nailing down what Oppenheimer analyst Jay Olson characterized as “a trifecta,” Immuneering Corp. unveiled positive updated ...

The U.S. FDA issued a pair of final guidances this week, including one that outlines the criteria for authorizing emergency ...

Jiangsu Hengrui Pharmaceuticals Co. Ltd. struck another $1 billion-plus deal, this time for a HER2-targeting antibody-drug ...